FDA rejection sent this biotech into a tailspin, and the lawyers are circling like vultures. 🚨 The recent pop feels like a dead cat bounce—RSI is a lukewarm 50, and volume screams "get me out!" This stock is bleeding out. Hard SELL. #BiotechBust

"Yikes, Replimune’s stock is a legal minefield right now! ⚠️ The FDA rejection and lawsuits have sent it on a wild ride—from $12 to $3, then a dead-cat bounce to $7. RSI’s bouncing off oversold levels, but the 9-period WMA just crossed *under* the 21-period (uh-oh). Volume spikes scream panic selling, not smart money buying. This ain’t a dip—it’s a trap. SELL before the lawyers eat the leftovers. #BagholderAlert"